Nasdaq Markets

Investors are always looking for stocks that are poised to beat at earnings season and Community Trust Bancorp, Inc. CTBI may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

Investors are always looking for stocks that are poised to beat at earnings season and Kimberly-Clark Corporation KMB may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

Investors are always looking for stocks that are poised to beat at earnings season and BOK Financial Corporation BOKF may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because BOK Financial is se

Advanced Micro Devices (AMD) has today announced the newest additions to its 3rd Generation AMD Ryzen desktop processor family, as part of its goal to deliver world class desktop performance to mainstream gamers. 

The company is launching the AMD Ryzen™ 3 3100 and the AMD Ryzen™ 3 3300X processors for just $99 and $120, respectively. These come alongside the AMD B550 Chipset for Socket AM4, which will offer support for 3rd Gen AMD Ryzen desktop processors.

According to AMD, these new Ryzen 3 desktop processors bring the powerful “Zen 2” core architecture to business users, gamers, and creators, leveraging Simultaneous Multi-Threading (SMT) technology for increased productivity.

It believes that with double the threads, twice the bandwidth, and a wide selection of motherboards in development, the AMD B550 chipset and the new Ryzen 3 desktop processors deliver the ideal processing solution from top to bottom.

“Games and applications are becoming more and more demanding, and with this, users are demanding more from their PCs,” commented Saeid Moshkelani, senior VP and general manager, client business unit.

“AMD is committed to providing solutions that meet and exceed those demands for all levels of computing... We’ve taken performance up a level, doubling the processing threads of our Ryzen 3 processors to propel gaming and multitasking experiences to new heights.”

The AMD Ryzen 3 3100 and AMD Ryzen 3 3300X are expected to be available from retailers worldwide beginning May 2020, while the AMD B550 motherboards is set for release from June 16, 2020.

Analysts have a cautiously optimistic Moderate Buy sentiment on AMD stock with an average price target of $54 (2% upside potential). Shares are falling 8% in Tuesday’s trading, bringing the stock’s year-to-date gain to 14%. (See AMD stock analysis on TipRanks).

Related News:
Apple Announces Major Expansion For Booming Services Segment
IBM Beats Quarterly Profit Estimates, Suspends 2020 Guidance
3 “Strong Buy” Penny Stocks That Could See Outsized Gains

Investors in VanEck Vectors ETF Trust - Junior Gold Miners ETF (Symbol: GDXJ) saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GDXJ options chain for the new June 19th contracts

Investors in Scorpio Tankers Inc (Symbol: STNG) saw new options begin trading this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STNG options chain for the new June 19th contracts and identified one put and on

Investors in Lear Corp. (Symbol: LEA) saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts

Investors in CIT Group Inc (Symbol: CIT) saw new options become available this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CIT options chain for the new June 19th contracts and identified one put and one ca

Investors in Sensata Technologies Holding PLC (Symbol: ST) saw new options become available this week, for the December 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration

Investors in Cenovus Energy Inc. (Symbol: CVE) saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading c

Investors in Fiat Chrysler Automobiles NV (Symbol: FCAU) saw new options become available this week, for the December 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration t

Investors in Takeda Pharmaceutical Co Ltd (Symbol: TAK) saw new options become available this week, for the June 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TAK options chain for the new June 19th contracts and identified one

The following are today's upgrades for Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.

The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.

The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f

The following are today's upgrades for Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.

The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.

Bio-Rad Laboratories Inc. (BIO) has started the commercial launch of its blood-based kit test which is used to screen if patients have developed antibodies against SARS-CoV-2, the virus causing COVID-19.

The company, which makes test systems for medical diagnostics products, said that the test can help clinicians detect patients who have been infected by SARS-CoV-2 by checking if they develop an immune reaction to the virus. The test can be done manually or by using automated equipment. Bio-Rad asserts that antibody testing provides a more complete account of infection rates and immunity to help public health officials in their efforts to reduce containment rates.

Clinical evaluation of the SARS-CoV-2 antibody test has demonstrated diagnostic specificity of more than 99% and diagnostic sensitivity of 98%, Bio-Rad said. In addition, cross-reactivity testing showed specificity of 100% with no response against other interfering specimens including non-CoV-2 coronaviruses.

On an update on regulatory hurdles, Bio-Rad said the company has met the CE mark requirements for Europe and has applied for Emergency Use Authorization status awarded by the U.S. Food and Drug Administration.

“Having applied for FDA Emergency Use Authorization and meeting the requirements for CE marking, we have begun shipping the test and are in the process of scaling up manufacturing to meet demand in the weeks and months ahead,”  Dara Wright, Bio-Rad Clinical Diagnostics Group EVP & President said.

Bio-Rad shares advanced 0.5% to $426.94 around midday trading on the New York Stock Exchange. Citigroup analyst Patrick B Donnelly yesterday raised the company’s price target to $480 from $425, while maintaining a Buy rating.

TipRanks data shows that Donnelly is 1 of 4 Wall Street analysts recommending investors buy the company’s stock adding up to a Strong Buy consensus rating. However, the $450 average price target suggests shares are poised to gain a mere 5.9% in the next 12 months. (See Bio-Rad Laboratories stock analysis on TipRanks).

Related News:
Pre-Market: Vaxart Pops 35% On Positive Covid-19 Vaccine Data
SAP Sees New Software Business Shelved; 1Q Earnings Miss Estimates
3 “Strong Buy” Penny Stocks That Could See Outsized Gains

InvestorPlace - Stock Market News, Stock Advice & Trading Tips